| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
24033 |
| Drug |
Omaveloxolone |
| Brand |
Skyclarys® |
| Indication |
For the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older |
| Rapid review commissioned |
02/08/2024 |
| Rapid review completed |
29/08/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of omaveloxolone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
25/09/2024 |
| Pre-submission consultation with Applicant |
04/02/2025 |
| Full submission received from Applicant |
02/07/2025 |
| Preliminary review sent to Applicant |
17/09/2025 |
| NCPE assessment re-commenced |
29/10/2025 |
